- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2020
- Why 4/10
- Trodelvy is already approved and commercialized with no imminent PDUFA or pivotal readout in the next ~12 months. The next hard catalyst would be Phase 2 NSCLC data (primary completion ~Sept 2026), but this is a Phase 2 readout at a diversified large-cap company, not a binary event. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
Trodelvy is a commercial-stage asset at Gilead with no near-term binary catalyst, investors should watch for label-expansion data readouts (e.g., Phase 2 NSCLC results) and quarterly sales trends rather than a single make-or-break event. The BioNTech collaboration is a non-financial supply agreement with data years away; it does not change Gilead's near-term outlook.
Price Chart
Executive Summary
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) targeting Trop-2, developed and marketed by Gilead Sciences (GILD). It is already FDA-approved in three indications: metastatic triple-negative breast cancer (2020/2021), HR+/HER2- metastatic breast cancer (2023), and metastatic urothelial cancer (2021). The filing hint pointing to BioNTech (BNTX) is incorrect, BioNTech only has a clinical trial collaboration with Gilead to test its drug pumitamig in combination with Trodelvy. As an already-approved, commercial-stage drug at a diversified large-cap biotech, Trodelvy contributes to Gilead's oncology growth but has no imminent binary regulatory catalyst. GILD trades near its 52-week high (~$156) with a consensus Buy rating and a mean price target of ~$160, implying ~5.7% upside.
How It Works
Trodelvy is an antibody-drug conjugate (ADC), a targeted cancer therapy that works like a "smart bomb." It combines an antibody that seeks out a protein called Trop-2 (found on many solid tumors) with a chemotherapy drug (SN-38). The antibody delivers the chemotherapy directly to cancer cells, sparing healthy tissue.
Trial Status
Trodelvy is FDA-approved in three indications. Ongoing trials include a Phase 2 study in first-line NSCLC (NCT05186974, Gilead-sponsored, primary completion estimated Sept 2026), a Phase 3 study combining with pembrolizumab in NSCLC (NCT05609968, Merck-sponsored, primary completion Jan 2027), and investigator-sponsored Phase 2 trials in bladder cancer and other solid tumors.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 NSCLC combination trial (NCT05186974) data readout, primary completion estimated Sept 2026
- Phase 3 NSCLC trial with Merck (NCT05609968), primary completion estimated Jan 2027
- Quarterly Trodelvy sales in Gilead earnings reports
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioNTech SE 6-K BNTX ·Originating report